• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 84
  • 26
  • 8
  • 6
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 134
  • 134
  • 63
  • 38
  • 20
  • 20
  • 14
  • 13
  • 13
  • 13
  • 12
  • 11
  • 11
  • 10
  • 10
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
131

Estudo da atividade antimicobacteriana e imunomoduladora do derivado tiofenólico, tiofenoacetamida, na infecção por Mycobacterium bovis (BCG)

Vergara, Fátima Maria Figueroa January 2010 (has links)
Submitted by Anderson Silva (avargas@icict.fiocruz.br) on 2012-11-30T13:18:28Z No. of bitstreams: 1 fatima_m_f_vergara_ioc_bcm_0016_2010.pdf: 988755 bytes, checksum: 3aad77ef91c57a6b8ccd02597caa98df (MD5) / Made available in DSpace on 2012-11-30T13:18:28Z (GMT). No. of bitstreams: 1 fatima_m_f_vergara_ioc_bcm_0016_2010.pdf: 988755 bytes, checksum: 3aad77ef91c57a6b8ccd02597caa98df (MD5) Previous issue date: 2010 / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Rio de Janeiro, RJ, Brasil / A tuberculose é uma doença infecto contagiosa que compromete, principalmente, as vias aéreas superiores e acomete humanos e outros animais. É causada por micobactérias do complexo Mycobacterium tuberculosis (MTB). Atualmente, aproximadamente, 1,7 bilhões de pessoas, em todo o mundo, estão infectadas e destes, cerca de 20 milhões são portadores de tuberculose ativa. Dados da OMS de 2009 estimam que 9,4 milhões de novos casos de tuberculose ocorreram em todo o mundo em 2008. Atualmente o tratamento da tuberculose se dá basicamente com medicamentos desenvolvidos na década de 60 e que não vem se mostrando eficazes nos casos de tuberculose resistente e na co-infecção com o HIV. Considerando esses fatos, é crescente a busca pelo desenvolvimento de fármacos capazes de atuar com eficácia e baixa toxicidade. O objetivo geral deste trabalho foi avaliar a ação bactericida do derivado tiofenólico, tiofenoacetamida (TAA), sobre o Mycobacterium bovis (BCG), sua ação imunomoduladora, sobre macrófagos murinos infectados e, ainda, sua ação in vivo no modelo experimental de pleurisia induzida em camundongos. O ensaio de Alamar blue demonstrou que o TAA tem ação bacteriostática sobre o M. bovis (BCG). A capacidade bactericida indireta sobre os macrófagos infectados com o M. bovis (BCG) foi avaliada pela contagem do número de unidades formadoras de colônia (UFC), e o tratamento com TAA foi eficaz em diminuí-las. Analisamos também se o TAA teria uma ação imunomoduladora sobre o macrófago infectado. Observamos que no macrófago infectado e pré-tratado com o TAA há diminuição de IL-12, TNF-α e óxido nítrico (NO), e ainda uma inibição da translocação de NF-κB, indicando uma ação antiinflamatória. Já o macrófago infectado e pós-tratado apresenta um aumento de NO, e mantém a inibição parcial de TNF-α, INF-γ, e IL-6. No modelo in vivo de pleurisia induzida pelo M. bovis (BCG), os camundongos foram pré-tratados em três doses distintas, 5; 25 ou 50 mg/kg, observando-se que o TAA é capaz de modular a migração de neutrófilos em 24 hs e em 15 dias e de células mononucleares em 24 hs. Constatamos que o TAA apresenta ação bactericida, diminuindo o número de UFC na cavidade pleural, discreta em 6 hs, mas intensa em 24 hs, assim como em 15 dias, em todas as doses utilizadas. Ao avaliarmos a ação do TAA sobre a liberação de NO, observamos que em 6 hs há uma diminuição na liberação que aumenta significativamente em 24 hs e que volta a diminuir em 15 dias. Ao avaliarmos a ação do TAA sobre a liberação de citocinas, observamos que há diminuição de IL-1β, a partir de 6 hs, de INF-γ a partir de 24 hs, e de IL-6 apenas no tempo de 6 hs e há aumento da liberação de IL-6, em 24 hs e 15 dias, e de IL-12 em todos os tempos avaliados. Analisando nossos resultados, pode-se sugerir que o TAA tem ação bactericida in vitro e in vivo sobre o M. bovis (BCG) e uma acentuada ação antiinflamatória quando utilizada como pré-tratamento. Entretanto na modulação do NO essa ação é revertida quando utilizado o pós-tratamento. O tratamento com TAA modula o processo inflamatório in vivo, auxiliando na sua resolução / Tuberculosis is a contagious infectious disease that compromises mainly the upper airways. This affects specially humans and also other animals. It is caused by mycobacterias from the Mycobacterium tuberculosis (MTB) complex. Nowadays approximately 1.7 billion people in the whole world are infected. Around 20 million are suffering with active tuberculosis. Data from WHO estimate that in 2008, 9.4 million new tuberculosis cases occurred all over the world. Tuberculosis treatment basically happens with drugs developed in the 60’s which has not been shown effective in treatment of resistant tuberculosis or in HIV co-infection. Considering these facts, is increasing the search in developing drugs able to act effectively and with low toxicity. The aim of this study was to evaluate the bactericidal action of thiophen derivative, thiopheacetamide (TAA), over Mycobacterium bovis (BCG), and its action in vivo in the experimental model of pleurisy induced by M. bovis (BCG), in mice. The test of Alamar Blue indicated that TAA present bacteriostatic action over M. bovis (BCG). The indirect bactericidal capacity over M. bovis (BCG) infected macrophages was evaluated through the counting of the colony-forming unit (CFU), and TAA treatment was efficient in decreasing those. We also analyzed whether TAA would have an immunomodulating action over the infected macrophage. We observed that the pre-treatment with TAA of infected macrophage promote a decrease in IL-12, TNF-α and nitric oxide (NO) levels, and inhibition of NF-κB translocation, indication a possible anti-inflammatory action. The pos-treated and infected macrophage presented an increase in NO, and keeps partial inhibition of TNF-α, INF-γ, e IL-6. We used the in vivo model of induced pleurisy through M. bovis (BCG) in mice, which were pre-treated with the doses of 5; 25 or 50 mg/kg. It is observed that TAA was capable of modeling the migration of neutrophil in 24 hours and in 15 days and also the mononuclear cells in 24 hours. We noted that TAA presents bactericidal action, decreasing the CFU number at the pleural cavity, discrete in 6 hours, but intense in 24 hours, such as in 15 days, at all tested doses. The evaluating of TAA action over the release of NO, show us that in 6 hours there was a decrease on the release of this mediator on the other hand NO increased significantly in 24 hours but decreased again in 15 days. The analysis of TAA action over the released of cytokines, demonstrated that there was a diminution of IL-1β and IFN-γ beginning at 6 and 24 hours after infection, respectively, and a inhibition of IL-6 production only 6 hours post infection. We noted an increased on the release of IL-12 in all evaluated times and of IL-6, in 24 hours and in 15 days after the M. bovis (BCG) infection. Our data indicate that this new compound, tiophenacetamide, presents in vitro and in vivo, an important antimicobacterial activity over M. bovis (BCG) and an immunomodulatory effect when used as a pretreatment
132

Optimisation of the lion (Panthera leo) specific interferon gamma assay for detection of tuberculosis in lions in South Africa

Khumalo, Nozipho Lindiwe 01 1900 (has links)
Mycobacterium bovis is the causative agent of bovine tuberculosis (BTB) which has a diverse host range. The maintenance host of BTB in South Africa is the African buffalo (Syncerus caffer). It is believed that lions get infected by feeding on infected buffalo or through wounds. The spread of the disease amongst lions has raised concern regarding the future of the animals and the impact on tourism in the country. Diagnoses of tuberculosis in free ranging wildlife is often dependent on post-mortem samples due to logistical challenges, the use of the lion specific interferon gamma release assay as an antemortem test offers a simpler methodology to testing live animals. The aim was to optimise an already developed assay by Maas et al.,2012 and to harmonise it with the Rhinoceros specific interferon gamma assay developed by Morar-Leather et al 2007. Optimisation of the interferon gamma specific ELISA included: determination of optimal concentrations for the capture and detection monoclonal antibodies; optimal concentrations for the conjugate and evaluation of alternative blocking agents. Different mitogens and incubation times were evaluated for the stimulation of whole blood as positive control in the assay. The optimum concentration for coating the plates with the capture monoclonal antibody was 2 g/ml. An optimum dilution of 1:5000 was selected for both the biotinylated detection monoclonal antibody and the streptavidin horseradish peroxidase conjugate. The assay was optimised using recombinant lion interferon gamma and the lower detection limit was calculated to be 109 pg/ml. Phosphate buffered saline with 1% bovine serum albumin was found to be Chapter 1 © University of South Africa iii a suitable blocking agent. Native interferon gamma was detected in whole blood samples from 5 lions and a 24 hour incubation time with PMA and ionomycin was selected as the optimal mitogen positive control. This assay system demonstrated good potential as an ante mortem test for the diagnosis of tuberculosis in lions. In conclusion, the assay can detect IFN- from supernatants harvested from whole blood cultures stimulated with specific antigens and mitogens / Agriculture and  Animal Health / M. Sc. (Agriculture)
133

The Lung Mucosa and its Impact on Mycobacterium tuberculosis Pathogenesis and Bacillus Calmette-Guerin Vaccine Efficacy

Moliva, Juan Ignacio 26 October 2017 (has links)
No description available.
134

The role of wild deer in the epidemiology and management of bovine tuberculosis in New Zealand

Nugent, Graham January 2005 (has links)
The eco-epidemiology of bovine tuberculosis (Tb) in wild deer (mainly red deer Cervus elaphus) in New Zealand was investigated. Bovine Tb is caused by Mycobacterium bovis. Specific aims were to clarify the likely routes of infection in deer, and to determine the status of deer as hosts of Tb, the likely rates and routes of inter- and intra-species transmission between deer and other wildlife hosts, the role of deer in spreading Tb, and the likely utility of deer as sentinels of Tb presence in wildlife. As the possum (Trichosurus vulpecula) is the main wildlife host of Tb, the research also included some investigation of transmission routes in possums. Patterns of infection were measured in 994 deer killed between 1993 and 2003. Tb prevalence varied between areas (range 8–36%). Few deer had generalised infection, with 21–68% of infected deer having no visible lesions, depending on the area. The retropharyngeal lymph nodes and oropharyngeal tonsils were commonly infected. No dependent fawns less than 0.75 years old were infected, indicating intra-species transmission is rare in wild deer. Where possums were not controlled, the net (cumulative) force of infection in young (1–4 y) deer was 0.10–0.24 per year in males and 0.09–0.12 per year in females, but much lower in older deer (less than 0.05 per year). Possum control reduced the net force of infection quickly, and eventually to zero. However, Tb persisted in possum-controlled areas through immigration of infected deer and, for almost a decade, through the survival of resident deer infected before possum control. Tb was lost from infected deer at an exponential rate of 0.13 per year, mostly as a result of deer recovering from infection rather than dying from it. Wild deer do die of Tb, but there was no discernible effect on age structure. The occurrence of infection in deer was not linked to the local deer or possum density at their kill sites (i.e. in their home range), but the area-wide prevalence of Tb in deer was closely correlated with Tb levels in possums, which were in turn correlated with area-wide measures of possum density. For wild deer in New Zealand, Tb is a persistent but usually inconsequential disease of the lymphatic system. It is acquired mainly by young independent deer, usually orally via the tonsils, and probably as a result of licking infected possums. Many species fed on deer carrion, including possums. Most possums encountering carrion did not feed on it, but a few fed for long periods. Other scavengers such ferrets (Mustela furo), hawks (Circus approximans), and weka (a hen-sized flightless native bird; Gallirallus australis) fed in a way that probably increased the infectivity of carrion to possums. Commercial deer hunting may have facilitated the historical establishment of Tb in possums. Scavenging (including cannibalism) and interactions with dead and dying possums are identified for the first time as potentially important routes for transmission of Tb to possums, and I develop new hypotheses involving peri- and post-mortem transmission in possums that explain many of the epidemiological patterns that are characteristic of the disease in possum. In continuous native forest, deer home range size averaged 250 hectares for six young females, and over twice that for two males. Over 90% of infected deer are likely to die within 2 km (females) or 6 km (males) of where they acquired Tb, but deer could occasionally carry Tb up to 30 km. Deer will be useful as sentinels, but only where other sentinels are rare, because the force of infection for a deer with a single infected possum in its home range is only 0.004 per year, compared to greater than 0.2 per year for deliberately released pigs. Deer are occasionally capable of initiating new cycles of infection in wildlife, but deer control is not essential to eradicate Tb from wildlife.

Page generated in 0.0732 seconds